Crescendo snares $70M Series B for its tumor-fighting tech
A tiny company in Cambridge, UK has hauled in one of the biggest European financing rounds of the year — $70 million in a Series B round — to push forward its oncology pipeline.
The biotech, called Crescendo Biologics, has a platform tech that’s the basis for a number of preclinical programs, including its lead drug CB307, which boosts an anti-tumor immune response right in the tumor microenvironment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.